Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

BLLN

HoldPremium Grower

BillionToOne, Inc. · Healthcare · United States · $4.4B · Avg Vol: $75M/d

61
StockRank
Get insider-trade alerts
Q
72
V
12
M
71
P/E (TTM)
138.0x
ROE
10.7%
D/E
0.3x
Dividend %

COMPANY DESCRIPTION

BillionToOne, Inc. is a molecular diagnostics company leveraging its proprietary quantitative molecular counting technology to develop highly accurate non-invasive tests for prenatal conditions and early cancer detection. Its competitive advantage lies in its unique technology, which provides unprecedented resolution and sensitivity, enabling precise detection of genetic variations from small biological samples. The company is positioned to disrupt traditional genetic and oncology diagnostics with its innovative platform.

FINANCIAL SUMMARY (USD)

Year202320242025CAGRTTM2026E2027EFwd CAGR
Revenue305.1M397.4M455.6M576.3M37.4%
EPS-2.10-1.050.180.720.160.2415.7%
Shares44.7M44.7M45.8M+2.4%42.6M
Debt108.9M143.9M
Equity480.1M
Op CF24.6M45.4M
Inv CF-8.9M
Fin CF288.8M
Loading 1Y...
PRICE (1Y)-29.4%
87.99103119134150Jul 30Aug 20Sep 10
SMA 50SMA 200

Close
$98.51
RSI (14)
56.6
52W High
$150.44
From 52W High
0.7%

SCORE BREAKDOWN

Quality
72
ROIC
6.5%59.6
ROE
10.7%72.2
GP/Assets
44.8%82.5
Op. Margin
5.0%52.0
FCF/Assets
5.2%71.1
Piotroski
497.9
Int. Cover
50.0x89.3
D/E Ratio
0.27x43.9
Current Ratio
11.69x89.7
Value
12
P/E (TTM)
138.0x5.8
EV/EBITDA
85.4x5.8
P/FCF
132.8x11.7
P/B
8.7x14.1
P/S
11.8x23.4
Div Yield
N/A
Momentum
71
52W High %
65%44.0
RS 6M
34%87.5
SMA 50/200
1.18x86.5
EPS Rev 4W
+44.2%97.7
EPS Rev 12W
+44.2%96.2
EPS Improve
+106%76.0
Q Growth
N/A

FUNDAMENTALS

Market Cap
$4.4B
P/E (Forward)
66.9x
Gross Margin
71.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BLLN are excluded.

TickerCompanyMkt CapStockRankSignal
BLLNBillionToOne, Inc.(you)$4.4B61Hold
VCYTVeracyte, Inc.$3.5B80Strong Buy
ADPTAdaptive Biotechnologies Corporation$4.0B38Hold
CDNACareDx, Inc.$2.6B75Buy
SHCSotera Health Company$5.5B81Strong Buy
CRLCharles River Laboratories International, Inc.$14.0B63Hold
NEONeoGenomics, Inc.$2.3B47Hold
RVTYRevvity, Inc.$14.4B64Hold
TWSTTwist Bioscience Corporation$8.9B47Hold
RDNTRadNet, Inc.$5.9B34Sell

Peer medians: ROE -30.7% · P/E 26.9x · Gross margin 58.1%

BillionToOne, Inc. (BLLN): Stock Score Summary

BillionToOne, Inc. (BLLN) has a MoatMap StockRank of 61/100 based on Quality (72/100), Value (12/100), and Momentum (71/100) factor scores. The current signal is HOLD.

BillionToOne, Inc. is a molecular diagnostics company leveraging its proprietary quantitative molecular counting technology to develop highly accurate non-invasive tests for prenatal conditions and early cancer detection. Its competitive advantage lies in its unique technology, which provides unprecedented resolution and sensitivity, enabling precise detection of genetic variations from small biological samples. The company is positioned to disrupt traditional genetic and oncology diagnostics with its innovative platform.

Key Financial Metrics

Price$98.51
Market Cap$4.4B
P/E (TTM)138.04
P/E (Forward)66.93
Price/Book8.67
Return on Equity10.7%
Return on Invested Capital6.5%
Debt/Equity0.27x
Gross Margin71.3%
Operating Margin5.0%
Revenue Growth64.4%
Free Cash Flow$33M

BillionToOne, Inc. operates in the Diagnostics & Research industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is BillionToOne, Inc.’s (BLLN) StockRank?
MoatMap’s StockRank for BillionToOne, Inc. (BLLN) is 61/100, with a Hold signal. It is a composite of Quality (72), Value (12), and Momentum (71) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does BillionToOne, Inc. have an economic moat?
BillionToOne, Inc. (BLLN) has a Quality factor score of 72/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is BillionToOne, Inc. a buy, hold, or sell?
MoatMap’s current signal for BillionToOne, Inc. (BLLN) is Hold, based on a StockRank of 61/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is BillionToOne, Inc. in?
BillionToOne, Inc. (BLLN) operates in the Healthcare sector, specifically the Diagnostics & Research industry (United States).